( 1 H δ 2.50 ppm;
13 C δ 39.5 ppm) using a Bruker ARX 400 Spectrometer ( 1 H: 300 MHz, 13 C: 100 MHz) at 298 K. Peak shapes in NMR spectra are indicated with the symbols 'd' (doublet), 'dd' (double doublet), 's' (singlet), 't' (triplet) and 'm' (multiplet). Chemical shifts (δ) are given in ppm and coupling constants J in Hz. LC-MS measurements were performed on a system equipped with a Waters 2795 Seperation Module (Alliance HT), Waters 2996 Photodiode Array Detector (190-750nm), Waters Alltima C18 (2.1x100mm, 3 μm) column, Phenomenex Kinetex C18 (2.1x50, 2.6 μm) column and LCT TM Orthogonal Acceleration Time of Flight Mass Spectrometer. Samples were run using 2 mobile phases: A = 1% CH 3 CN, 0.1% formic acid in water and B = 1% water and 0.1% formic acid in CH 3 CN. Data processing was performed using Waters MassLynx Mass Spectrometry Software 4.1 (deconvulation with Maxent1 function). Pereparative HPLC was performed on a Shimadzu Prominence HPLC system equipped with a Waters Atlantis prep T3 TM (10x150mm, 5 μm) column, using 2 mobile phases: A = 0.1% TFA in water and B = 0.1% formic acid in CH 3 CN. Nano-LC-MSMS was performed on a Dionex U3000 nano system coupled to a Thermo LTQ Orbitrap XL Mass Spectrometer using a Top 5 instrument method ( 1 x FT-MS scan (mz range 335-1800 ; 60K resolution) and 5 x IT MSMS scans ) over 40 min (5  40% B), using 2 mobile phases: A = 0.1% formic acid in water and B = 10% water, 0.1% formic acid in CH 3 CN. Results were analyzed with Thermo Scientific Proteome Discoverer 1.3 software.
LC-MS methods
Method 1: Waters Alltima C18, 2.1×100 mm, 3 μm); flow rate = 0.4 mL/min, runtime = 20 min, column T = 40°C. Gradient: 0 − 1 min: 5% B; 1 − 11 min:  95% B; 11 − 16 min: 95% B.
Method 2: Phenomenex Kinetex C18, (2.1×50 mm), 2.6 μm); flow rate = 0.8 mL/min, runtime = 6 min, column T = 40°C. Gradient: 0 − 0.5 min: 5% B; 0.5 − 4 min:  95% B; 4 −5.5 min: 95% B.
Preperative HPLC method
Flow rate = 7.5 mL/min, runtime 35 min, column T = 40°C. Gradient: 0 − 5 min: 5% B; 5 − 8 min:  25% B; 8 −30 min:  60% B; . 30 −33 min:  95% B; 33 −35 min: 95% B.
General Fmoc SPPS Strategy
SPPS was performed on a Syro II MultiSyntech Automated Peptide synthesizer using standard 9-fluorenylmethoxycarbonyl (Fmoc) based solid phase peptide chemistry at 25 μmol scale, using fourfold excess of amino acids in NMP relative to pre-loaded Fmoc amino acid trityl resin (0.2 mmol/g, Rapp Polymere GmbH), PyBOP (4 equiv) and DIPEA (8 equiv) were used as condensing reagents. All amino acids were Fmoc protected, except for the final N-terminal amino acids which were introduced as the corresponding Boc derivative. The following protected amino acid and pseudoproline dipeptide building blocks were used during Pup synthesis: 
Use of dipeptide pseudoproline building blocks
Three Pup(1-63) sequences were synthesized using one (B), two (C) or no (A) pseudoproline dipeptide building block(s), the crude products were analyzed by SDS page and HPLC-MS (method 2). The position of the pseudoprolines in the Pup sequence is marked with an underscore. Introduction of 2 pseudoproline dipeptide building blocks largely prevented formation of side products which arise from terminations and deletions.
A MAQEQTKRGGGGGDDDDIAGSTAAGQERREKLTEETDDLLDEIDDVLEENAEDFVRAYVQKGG B MAQEQTKRGGGGGDDDDIAGSTAAGQERREKLTEETDDLLDEIDDVLEENAEDFVRAYVQKGG C MAQEQTKRGGGGGDDDDIAGSTAAGQERREKLTEETDDLLDEIDDVLEENAEDFVRAYVQKGG
Synthesis of H-Glu-OtBu
Fmoc-Glu(AMC)-OtBu (2). Under argon, 1-Chloro-N,N,2-trimethyl-1-propenylamine (Ghosez' reagent) (440 µL, 3.3 mmol) was added to a cooled (0°C) and stirred solution of Fmoc-Glu(AMC)-OtBu (700.0 mg, 1.6 mmol) in dry DCM (10 mL). The resulting mixture was immediately transferred to a separate flask containing a stirred solution of AMC (316.0 mg, 1.8 mmol) in dry DMF (40 mL) and the resulting mixture was stirred at room temperature under argon. After 16 h an extra portion of the Ghosez' reagent (220 µL, 1.65 mmol) was added and stirring was continued for one additional hour to ensure complete conversion of the Fmoc-Glu-OtBu starting material, as was confirmed by HPLC-MS analysis (program 2). Volatiles were removed in vacuo and the residue was taken up in EtOAc (50 mL) and washed with 1N KHSO 4 (3 × 50 mL) and Brine (3 × 50 mL) and dried (Na 2 SO 4 ). Fmoc-Glu(AMC)-OtBu (2). Under Nitrogen, POCl 3 (504 L, 5.4 mmol) was added dropwise to a cooled (-15°C) and stirred mixture of AMC (0.87g, 4.9 mmol) and Fmoc-Glu(AMC)-OtBu (2.0 g, 4.7 mmol) in dry DMF/Pyridine (2:1 v/v, 100 mL). The reaction mixture was allowed to warm up to room temperature and stirring was continued for 16 h before the solvents were removed in vacuo. The residu was coevapporated with toluene and taken up in EtOAc (300 mL), washed with 1N KHSO 4 (2 × 200 mL) and Brine (2 × 200 mL) and dried (Na 2 SO 4 ). The product was isolated by flash column chromatography (eluent: Et 2 O) as a white foam (600 mg, 21%). 
H-Glu(AMC)-OtBu (3)
. A portion of 2 (200 mg 0.34 mmol) was dissolved in diethylamine/dicholoromethane (1:1 v/ v, 16 mL) and stirred at room temperature. After 3h the reaction mixture was concentrated
Synthesis of and characterization compounds 1a -c and Ub-AMC

General method for the C-terminal modification of PupQ (1)
The PupQ sequence was synthesized on a trityl resin following the general procedure. Then, the resin bound polypeptide was treated with 5 mL of DCM/HFIP (7:3 v/v) for 30 min and filtered. This DCM/HFIP treatment was repeated once more and the resin was rinsed with DCM (3 × 5 mL). The combined filtrates were concentrated, coevapporated with DCM and dried under high vacuum. The partially protected peptide residue ( Ub-AMC. The synthesis of ubiquitin-AMC was performed following the procedure as was described earlier. 
MAQEQTKRGGGGGDDDDIAGSTAAGQERREKLTEETDDLLDEIDDVLEENAEDFVRAYVQKGG-Glu(AMC) (1a
Dop activity assays Photometric assays
Reactions contained Dop-His 6 (3-3.5 g), 2 substrate (2 M), ATP (2.5 mM unless otherwise indicated), MgCl 2 (20 mM), DTT (1 mM), and NaCl (50 mM) in Tris (50 mM, pH8) in a final volume of 100 L in a 96-well plate format. Reactions were monitored by measuring the increase in fluorescence emission at 460nm (ex = 355 nm) that correlates with hydrolysis of AMC from the substrate.
For Mtb lysate experiments, Mtb were grown to an OD 580 = 1 -1.2 after which 50 OD equivalents were harvested and washed with 25 mL of 0.05% Tween-80 in PBS. The cells were resuspended in 1 mL of 100 mM Tris, pH8, 1 mM EDTA and transferred to bead beating tubes with 250 L of zirconia silica beads. Cells were lysed by bead beating three times for 30 sec each time. Lysates were filtered through 0.45 m filters, glycerol was added to 12% final volume. Lysate samples were either used immediately or stored at -20°C for further use. Lysate reactions contained 40 L lysate, 3 M substrate 1a, 5 mM ATP, 20 mM MgCl 2 , 1 mM DTT, 1 x energy regeneration solution (Boston Biochem) and 50 mM NaCl in 50 mM Tris, pH8 in a final volume of 100 L.
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Mass spectrometric assays
To a solution of peptide 1a, 1b, 1c or Ub-AMC (3.3 µM) in assay buffer (containing: 2.5 mM ATP, 20 mM MgCl 2 , 1 mM DTT, and 50 mM NaCl in 50 mM Tris, pH8), Dop-His 6 was added and the mixture was incubated at RT for 2 h. As a control, a solution of the peptide (3.3 µM) in assay buffer without added Dop-His 6 was incubated at RT for 2 h. After 2 h 60 µL CH 3 CN was added to both reaction vials, the samples were centrifuged at 13.000 rpm for 5 min. Aliquots (25 µL) were taken from each mixture for ESMS analysis. Figure S1 ESMS analysis of peptides 1a -c and Ub-AMC after incubation in the Dop assay. 
Ub-AMC without DOP
